AEON Biopharma Statistics
Total Valuation
AEON Biopharma has a market cap or net worth of $7.95 million. The enterprise value is $20.28 million.
Important Dates
The last earnings date was Friday, November 14, 2025, before market open.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AEON Biopharma has 11.84 million shares outstanding. The number of shares has decreased by -91.04% in one year.
| Current Share Class | 11.84M |
| Shares Outstanding | 11.84M |
| Shares Change (YoY) | -91.04% |
| Shares Change (QoQ) | +4.91% |
| Owned by Insiders (%) | 28.70% |
| Owned by Institutions (%) | 14.18% |
| Float | 8.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.90
| Current Ratio | 0.90 |
| Quick Ratio | 0.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -165.52% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -3,333.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$600 |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.61% in the last 52 weeks. The beta is 0.75, so AEON Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -98.61% |
| 50-Day Moving Average | 0.92 |
| 200-Day Moving Average | 0.83 |
| Relative Strength Index (RSI) | 32.94 |
| Average Volume (20 Days) | 243,743 |
Short Selling Information
The latest short interest is 37,337, so 0.32% of the outstanding shares have been sold short.
| Short Interest | 37,337 |
| Short Previous Month | 114,239 |
| Short % of Shares Out | 0.32% |
| Short % of Float | 0.44% |
| Short Ratio (days to cover) | 0.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.87M |
| Pretax Income | -3,000 |
| Net Income | -3,000 |
| EBITDA | -16.79M |
| EBIT | -16.87M |
| Earnings Per Share (EPS) | -$0.00 |
Full Income Statement Balance Sheet
The company has $5.93 million in cash and $18.26 million in debt, giving a net cash position of -$12.33 million or -$1.04 per share.
| Cash & Cash Equivalents | 5.93M |
| Total Debt | 18.26M |
| Net Cash | -12.33M |
| Net Cash Per Share | -$1.04 |
| Equity (Book Value) | -19.87M |
| Book Value Per Share | -1.71 |
| Working Capital | -816,000 |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$13.22 million and capital expenditures -$4,000, giving a free cash flow of -$13.22 million.
| Operating Cash Flow | -13.22M |
| Capital Expenditures | -4,000 |
| Free Cash Flow | -13.22M |
| FCF Per Share | -$1.12 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AEON Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 91.04% |
| Shareholder Yield | 91.04% |
| Earnings Yield | -0.04% |
| FCF Yield | -166.21% |
Analyst Forecast
The average price target for AEON Biopharma is $7.20, which is 971.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.20 |
| Price Target Difference | 971.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 26, 2025. It was a reverse split with a ratio of 1:72.
| Last Split Date | Feb 26, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:72 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |